Cell biology: Chromosome alignment and segregation regulated by ubiquitination of survivin

Science

Volumn 310, Issue 5753, 2005, Pages 1499-1504

  Vong, Queenie P ^a   Cao, Kan ^a,b   Li, Hoi Y ^a,d   Iglesias, Pablo A ^c   Zheng, Yixian ^a,b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Johns Hopkins University   (United States)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADATION; CHROMOSOMES; ENZYMES;

CELL BIOLOGY; KINETOCHORES; MICROTUBULES; MITOSIS;

CYTOLOGY;

BINDING PROTEIN; LYSINE; POLYCLONAL ANTIBODY; SURVIVIN; UBIQUITIN; AURKB PROTEIN, MOUSE; BIRC5 PROTEIN, HUMAN; EGG PROTEIN; HFAM PROTEIN, HUMAN; INCENP PROTEIN, HUMAN; INCENP PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN; NONHISTONE PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEINASE; SIX PROTEIN, XENOPUS; TUMOR PROTEIN; XENOPUS PROTEIN; XFAM PROTEIN, XENOPUS;

BIOLOGY;

ANIMAL CELL; ARTICLE; CENTROMERE; CHROMOSOME SEGREGATION; CHROMOSOME STRUCTURE; GENETIC LINKAGE; METAPHASE; MICROTUBULE; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SISTER CHROMATID; SPINDLE CELL; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; HELA CELL; HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN BINDING; XENOPUS;

ANIMALIA;

AMINO ACID SEQUENCE; ANIMALS; CENTROMERE; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME SEGREGATION; EGG PROTEINS; ENDOPEPTIDASES; HELA CELLS; HUMANS; LYSINE; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN; XENOPUS; XENOPUS PROTEINS;

EID: 28544453333     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1120160     Document Type: Article

References (37)

1. M. Carmena, W. C. Earnshaw, Nat. Rev. Mol. Cell Biol. 4, 842 (2003).
2. P. D. Andrews, E. Knatko, W. J. Moore, J. R. Swedlow, Curr. Opin. Cell Biol. 15, 672 (2003).
3. V. Beardmore, L. Ahonen, G. Gorbsky, M. Kallio, J. Cell Sci. 117, 4033 (2004).
4. INS was made by changing wobble codons (GCA GTT AGC GGG TGG AAG, changed nucleotides are in bold) corresponding to hFAM-s1 siRNA sequence using GeneEditor (Promega). Antibody to Xenopus Survivin was raised against glutathione S-transferase (GST) Xenopus Survivin and affinity purified using cleaved Survivin. Antibodies against hFAM were raised against each of four peptides (TPPDEQGQG-DAPPQLED, CAPDEHESPPPEDAP, QRAQENYEG-SEEVSPPQTKDQ, and GDEKQDNESNVDPRDDV) (36) and one GST fusion of the C-terminal fragment (amino acids 2347 to 2547) of hFAM. All were affinity purified against the respective antigens. Mouse Ufd1 was cloned into the pEF6/V5-His vector. Ufd1 antibodies were raised against GST-Ufd1 fusion protein and purified against His-tagged Ufd1. Antibodies against tubulin (Sigma), ACA (Antibodies Incorporated), human Survivin (R&D systems), human Aurora B (BD Biosciences), HA (Roche), Myc (Santa Cruz), and control immunoglobulin G (IgG) (Jackson Laboratory) were purchased. Antibodies against phosphorylated MCAK were described previously (27). Immunoprecipitation and immunofluorescence were carried out as described previously (15).
5. M. Jones et al., Hum. Mol. Genet. 5, 1695 (1996).
6. T. Noma et al., Mech. Dev. 1195, S91 (2002).
7. S. Wood et al., Mech. Dev. 63, 29 (1997).
8. J. Fischer-Vize, G. Rubin, R. Lehmann, Development 116, 985 (1992).
9. Y. Huang, J. Fischer-Vize, Development 122, 3207 (1996).
10. X. Chen, B. Zhang, J. Fischer, Genes Dev. 16, 289 (2002).
11. A. Cadavid, A. Ginzel, J. Fischer, Development 127, 1727 (2000).
12. Z. Wu, Q. Li, M. Fortini, J. Fischer, Dev. Genet. 25, 312 (1999).
13. S. Taya et al., J. Cell Biol. 142, 1053 (1998).
14. R. Murray, L. Jolly, S. Wood, Mol. Biol. Cell 15, 1591 (2003).
15. K. Cao, R. Nakajima, H. H. Meyer, Y. Zheng, Cell 115, 355 (2003).
16. H. Richly et al., Cell 120, 73 (2005).
17. A. Carvalho, M. Carmena, C. Sambade, W. C. Earnshaw, S. P. Wheatley, J. Cell Sci. 116, 2987 (2003).
18. CAT, or pV5 vector for at least 48 hours before siRNA transfection. Cells were analyzed 72 hours after siRNA transfection.
19. W. Earnshaw, B. Bordwell, C. Marino, N. Rothfield, J. Clin. Invest. 77, 426 (1986).
20. R. Gassmann et al., J. Cell Biol. 166, 179 (2004).
21. P. Andrews et al., Dev. Cell 6, 253 (2004).
22. W. Lan et al., Curr. Biol. 14, 273 (2004).
23. H. Li, D. Wirtz, Y. Zheng, J. Cell Biol. 160, 635 (2003).
24. HeLa cells were treated with hFAM-s1 or control siRNA for ∼24 hours and then transfected with Survivin-GFP. FLIP or FRAP was carried out 48 to 72 hours after transfection. Detailed descriptions of the kinetic modeling of FLIP and FRAP can be found in (26).
25. M. Delacour-Larose, A. Mollar, D. A. Skoufias, R. L. Margolis, S. Dimitrov, Cell Cycle 3, 1418 (2004).
26. Materials and methods are available as supporting materials on Science Online.
27. L. Sun, Z. Chen, Curr. Opin. Cell Biol. 16, 119 (2004).
28. CAT or the respective vector controls followed by the same treatment and analyses described above.
29. X. J. Yang, Oncogene 3, 653 (2005).
30. M. A. Verdecia et al., Nat. Struct. Biol. 7, 602 (2000).
31. C. Hoege, G.-L. Pfander, G. Pyrowolakis, S. Jentsch, Nature 419, 135 (2002).
32. I. Wertz et al., Nature 430, 694 (2004).
33. J. Zhao, T. Tenev, L. Martins, J. Downward, N. Lemoine, J. Cell Sci. 23, 4363 (2000).
34. C. Pickart, Cell 116, 181 (2004).
35. S. Wing, Inter. J. Biochem. Cell Biol. 35, 590 (2003).
36. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
37. We thank J. Swedlow, S. Wood, H. Meyer, and T. Dawson for antibodies and constructs B. Lane for protein sequencing; C. Pickart for helpful advice on ubiquitination assays; O. Martin and R. Chen for excellent technical support; and M. Guo, D. Koshland, J. Yanowitz, and the members of Zheng lab for helpful comments. This work was supported by Howard Hughes Medical Institution and by National Institute of General Medical Sciences grant no. GM56312.